EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02)

Tumormikroumgebung beschreibt unterschiedliche Ansprecher auf Trastuzumab Emtansin bei HER2-positivem metastasiertem Brustkrebs nach Pyrotinib: explorative Biomarkeranalyse einer Phase-II-Studie (NJMU-BC02)

Hong Pan, Ji Wang, Yue Sun, Fanfan Li, Chang Sun, Mingduo Liu, Hong Xu, Jing Tao, Xinrui Mao, Cong Wang, Shui Wang, Wei Li und 2 weitere

Signal Transduction and Targeted Therapy · 29.09.2025 · 10 (1)

DOI: 10.1038/s41392-025-02409-2 ↗

Auf einen Blick

Bei 36 Patient:innen mit HER2-positivem metastasiertem Brustkrebs zeigte T-DM1 eine ORR von 47,2 %. Einzelzell-RNA-Sequenzierung identifizierte Merkmale, die mit gutem Ansprechen assoziiert waren.

Fragestellung

Wie wirksam und sicher ist T-DM1 bei HER2-positivem metastasiertem Brustkrebs nach Versagen von Pyrotinib und/oder Trastuzumab plus Pertuzumab, und welche Biomarker könnten das Ansprechen vorhersagen?

Methode

Multizentrische Phase-II-Studie (NCT06125834) mit 36 Teilnehmer:innen; T-DM1 alle 21 Tage bis Progression oder inakzeptabler Toxizität; explorative Biomarkeranalyse mit Einzelzell-RNA-Sequenzierung.

Ergebnisse

ORR 47,2 % (17/36; 95 %-KI 30,4–64,5), DCR 66,7 % (24/36; 95 %-KI 49,0–81,4), CBR 50,0 % (18/36; 95 %-KI 32,9–67,1). Medianes PFS 6,6 Monate (95 %-KI 5,2–NA).

Schlussfolgerung der Autor:innen

Die Autor:innen schließen, dass T-DM1 bei diesen Patient:innen wirksam ist und ein messbares Sicherheitsprofil hat. Erste Befunde deuten auf potenzielle Biomarker zur Vorhersage des Ansprechens hin.

Kernaussagen

  • ORR unter T-DM1: 47,2 % (17/36)
  • Medianes PFS: 6,6 Monate
  • Einzelzell-Analysen lieferten Hinweise auf mögliche Biomarker

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Signal Transduction and Targeted Therapy, online erschienen am 29.09.2025. Verfasst von Hong Pan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Department of General Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Ado-Trastuzumab Emtansine, Biomarkers, Tumor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China (National Science Foundation of China).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trastuzumab emtansine (T-DM1) has been approved for the treatment of HER2-positive breast cancer. However, the efficacy of T-DM1 for patients after failure of pyrotinib and/or trastuzumab plus pertuzumab has not been clear. Additionally, no biomarker has been reported to predict the effect of T-DM1. In this multicenter phase II trial (NCT06125834), 36 participants with HER2-positive metastatic breast cancer were enrolled to receive T-DM1 therapy on a 21-day cycle until progression or unacceptable toxicity. The primary endpoint was the objective response rate (ORR). The secondary endpoints included the disease control rate (DCR), clinical benefit rate (CBR), progression-free survival (PFS), and toxicity. The primary endpoint was an ORR of 47.2% (17/36, 95% CI 30.4–64.5). The treatment exhibited a manageable toxicity profile. The DCR was 66.7% (24/36, 95% CI 49.0–81.4), and the CBR was 50.0% (18/36, 95% CI 32.9–67.1). The median PFS was 6.6 (95% CI 5.2-NA) months. Single-cell RNA sequencing revealed that the low cell cycle activity of cancer cells, activated macrophages and CD8+ T cells was associated with the good efficacy of T-DM1, which was validated in a neoadjuvant cohort. This study suggests that T-DM1 is effective with a measurable safety profile in patients with metastatic HER2-positive breast cancer after failure of pyrotinib and/or trastuzumab plus pertuzumab. Our preliminary findings suggest potential biomarkers that may help predict T-DM1 efficacy, generating hypotheses for novel therapeutic targets that may address T-DM1 resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesAdo-Trastuzumab EmtansineBiomarkers, TumorTumor MicroenvironmentAcrylamidesAminoquinolinesHumansFemaleMiddle AgedAdultAgedNeoplasm Metastasis

Substanzen

Erb-b2 Receptor Tyrosine KinasesAdo-Trastuzumab EmtansineBiomarkers, TumorAcrylamidesAminoquinolinesERBB2 protein, humanpyrotinib

Autor:innen und Institutionen

  • Department of Breast Surgery, Department of General Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
  • Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
  • Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Department of Medical Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Department of General Surgery, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, China.

ORCID-Profile: Wenbin Zhou

Förderung

  • National Natural Science Foundation of China (National Science Foundation of China)

Zitieren

APA

Pan, H., Wang, J., Sun, Y., Li, F., Sun, C., Liu, M., Xu, H., Tao, J., Mao, X., Wang, C., Wang, S., Li, W., Ding, Q., & Zhou, W. (2025). Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02). Signal Transduction and Targeted Therapy, 10(1). https://doi.org/10.1038/s41392-025-02409-2

Vancouver

Pan H, Wang J, Sun Y, Li F, Sun C, Liu M, et al. Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02). Signal Transduction and Targeted Therapy. 2025;10(1). doi:10.1038/s41392-025-02409-2

BibTeX
@article{Pan2025,
  author = {Pan, Hong and Wang, Ji and Sun, Yue and Li, Fanfan and Sun, Chang and Liu, Mingduo and Xu, Hong and Tao, Jing and Mao, Xinrui and Wang, Cong and Wang, Shui and Li, Wei and Ding, Qiang and Zhou, Wenbin},
  title = {Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02)},
  journal = {Signal Transduction and Targeted Therapy},
  year = {2025},
  volume = {10},
  number = {1},
  doi = {10.1038/s41392-025-02409-2}
}
Kostenlos starten →